Pan‐Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System

ABSTRACT Background The cumulative, health system‐wide survival benefit of immune checkpoint inhibitors (ICIs) is unclear, particularly among real‐world patients with limited life expectancies and among subgroups poorly represented on clinical trials. We sought to determine the health system‐wide su...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Sean R. Miller, Matthew Schipper, Lars G. Fritsche, Ralph Jiang, Garth Strohbehn, Erkin Ötleş, Benjamin H. McMahon, Silvia Crivelli, Rafael Zamora‐Resendiz, Nithya Ramnath, Shinjae Yoo, Xin Dai, Kamya Sankar, Donna M. Edwards, Steven G. Allen, Michael D. Green, Alex K. Bryant
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Wiley 2024-11-01
سلاسل:	Cancer Medicine
الموضوعات:	check point control clinical cancer research clinical observations immune checkpoint inhibitors
الوصول للمادة أونلاين:	https://doi.org/10.1002/cam4.70379
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!